The pharmaceutical company filed with the FDA to sell its experimental treatment albiglutide.
The market is growing and the opportunities are there, but so are the risks.
With the help of an imaging agent, the pharma is pursuing what it hopes will be a blockbuster drug.
Optimism that a budget agreement is close could extend equities' rally.
Darden is downgraded to 'neutral,' and Burger King is initiated with a 'buy.'
Even with the prospect of dividend taxes going up, my sense is that income-generating stocks will remain in favor going forward.
The pharma wins US approval for a new rheumatoid arthritis pill, but Abbott's existing treatment isn't likely to suffer a meaningful hit to sales anytime soon.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Fed may start tapering in just a few months. Here are a few of the likely winners and losers.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Even those who don't like to shop are probably hitting the stores this month. Here's what to be on the lookout for and here's what to avoid.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.